Skip to content
10-Q

Quarterly Report

NewAmsterdam Pharma Company N.V. NAMS NAMSW

0001193125-26-210272

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 29, 2026 116.9M sh
Shares Diluted Q1 2026 · Mar 31, 2026 121.72M sh
Shares Diluted Q1 2026 · Mar 31, 2025 116.12M sh
Capex Q1 2026 · Mar 31, 2026 $38K
Capex Q1 2026 · Mar 31, 2025 $16K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$30.6M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$36.47M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $457.61M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $490M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $748.42M
Stockholders Equity Q1 2026 · Mar 31, 2026 $665.22M
Stockholders Equity Q1 2026 · Dec 31, 2025 $683.43M
Stockholders Equity Q1 2026 · Mar 31, 2025 $777.36M
Stockholders Equity Q1 2026 · Dec 31, 2024 $757.5M
Current Liabilities Q1 2026 · Mar 31, 2026 $67.42M
Current Liabilities Q1 2026 · Dec 31, 2025 $85.79M
Total Liabilities Q1 2026 · Mar 31, 2026 $67.42M
Total Liabilities Q1 2026 · Dec 31, 2025 $85.85M
Current Assets Q1 2026 · Mar 31, 2026 $658.04M
Current Assets Q1 2026 · Dec 31, 2025 $675.7M
Total Assets Q1 2026 · Mar 31, 2026 $732.64M
Total Assets Q1 2026 · Dec 31, 2025 $769.28M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.40
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.34
Eps Basic Q1 2026 · Mar 31, 2026 −$0.40
Eps Basic Q1 2026 · Mar 31, 2025 −$0.34
Sga Expense Q1 2026 · Mar 31, 2026 $23.45M
Sga Expense Q1 2026 · Mar 31, 2025 $27.15M
Rd Expense Q1 2026 · Mar 31, 2026 $38.01M
Rd Expense Q1 2026 · Mar 31, 2025 $44.75M
Net Income Q1 2026 · Mar 31, 2026 −$48.44M
Net Income Q1 2026 · Mar 31, 2025 −$39.53M
Operating Income Q1 2026 · Mar 31, 2026 −$58.42M
Operating Income Q1 2026 · Mar 31, 2025 −$68.93M
Revenue Q1 2026 · Mar 31, 2026 $3.04M
Revenue Q1 2026 · Mar 31, 2025 $2.98M